Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Turid Aas

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Plos One|May 11, 2011
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxelRanjan Chrisanthar, Stian Knappskog, Erik Løkkevik, et al.
Scientific Reports|February 21, 2020
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroupsCecilie Askeland, Elisabeth Wik, Kenneth Finne, et al.
The Journal of Pathology. Clinical Research|September 30, 2025
Reduced GATA3 expression associates with immuno-metabolic alterations and aggressive features in breast cancerAnna Km Sæle, Amalie A Svanøe, Cecilie Askeland, et al.
European Journal of Human Genetics : EJHG|September 10, 2015
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus studyHildegunn Høberg-Vetti, Cathrine Bjorvatn, Bent E Fiane, et al.
European Thyroid Journal|February 26, 2019
Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based StudyElse Marie Opsahl, Lars Andreas Akslen, Ellen Schlichting, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 29, 2024
Age-Related Clusters and Favorable Immune Phenotypes in Young Breast Cancer PatientsLise Martine Ingebriktsen, Amalie Abrahamsen Svanøe, Anna Kristine Myrmel Sæle, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II studyChristina Engebrethsen, Synnøve Yndestad, Mari E Rasmussen, et al.
Scientific Reports|April 26, 2017
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancerKristi Krüger, Elisabeth Wik, Gøril Knutsvik, et al.
International Journal of Cancer|February 6, 2024
Age-related phenotypes in breast cancer: A population-based studyAmalie A Svanøe, Rasmus O C Humlevik, Gøril Knutsvik, et al.
Genome Medicine|August 10, 2022
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapyAndreas Venizelos, Christina Engebrethsen, Wei Deng, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Plos One|May 11, 2011
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxelRanjan Chrisanthar, Stian Knappskog, Erik Løkkevik, et al.
Scientific Reports|February 21, 2020
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroupsCecilie Askeland, Elisabeth Wik, Kenneth Finne, et al.
The Journal of Pathology. Clinical Research|September 30, 2025
Reduced GATA3 expression associates with immuno-metabolic alterations and aggressive features in breast cancerAnna Km Sæle, Amalie A Svanøe, Cecilie Askeland, et al.
European Journal of Human Genetics : EJHG|September 10, 2015
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus studyHildegunn Høberg-Vetti, Cathrine Bjorvatn, Bent E Fiane, et al.
European Thyroid Journal|February 26, 2019
Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based StudyElse Marie Opsahl, Lars Andreas Akslen, Ellen Schlichting, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 29, 2024
Age-Related Clusters and Favorable Immune Phenotypes in Young Breast Cancer PatientsLise Martine Ingebriktsen, Amalie Abrahamsen Svanøe, Anna Kristine Myrmel Sæle, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II studyChristina Engebrethsen, Synnøve Yndestad, Mari E Rasmussen, et al.
Scientific Reports|April 26, 2017
Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancerKristi Krüger, Elisabeth Wik, Gøril Knutsvik, et al.
International Journal of Cancer|February 6, 2024
Age-related phenotypes in breast cancer: A population-based studyAmalie A Svanøe, Rasmus O C Humlevik, Gøril Knutsvik, et al.
Genome Medicine|August 10, 2022
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapyAndreas Venizelos, Christina Engebrethsen, Wei Deng, et al.
Pageof 5